Human healthcare is one of the most important issues in society to ensure that patients receive the care they require as quickly as possible. One of the disorders that affects the global population and is becoming more prevalent is thyroid disease. Medical information systems are crucial in their capacity to diagnose thyroid disease. Artificial intelligence has recently offered fresh approaches to the existing clinical treatment issues and has demonstrated promising results for individualized diagnosis and therapy planning. Hence, this paper proposes an optimized multi-class classification model, which depends on XGBoost to classify patients with different types of thyroid disease. The main contribution is to (i) propose a Multiclass-Classification for the purpose of diagnosing three different thyroid diseases, (ii) raise the row dataset's feature selection accuracy for classification. (iii) utilize the highly selective XGBoost algorithm for the chosen characteristics, (iv) show that The XGBoost has the best performance and recall, making it the top choice for data analysis in terms of classifying thyroid disease, and (v) improve upon findings from earlier studies by doing the proposed study. XGBoost is trained and tested using UCI machine learning repository dataset of thyroid disease. In addition to build the model with the optimized hyperparameters to achieve and compare the gained results aiming to get the best score of accuracy. From the results, it is shown that the optimized XGBoost achieved 99% accuracy as a win over performing compared with the state of arts models.

In computer vision, emotion recognition using facial expression images is considered an important research issue. Deep learning advances in recent years have aided in attaining improved results in this issue. According to recent studies, multiple facial expressions may be included in facial photographs representing a particular type of emotion. It is feasible and useful to convert face photos into collections of visual words and carry out global expression recognition. The main contribution of this paper is to propose a facial expression recognition model (FERM) depending on an optimized Support Vector Machine (SVM). To test the performance of the proposed model (FERM), AffectNet is used. AffectNet uses 1250 emotion-related keywords in six different languages to search three major search engines and get over 1,000,000 facial photos online. The FERM is composed of three main phases: (i) the Data preparation phase, (ii) Applying grid search for optimization, and (iii) the categorization phase. Linear discriminant analysis (LDA) is used to categorize the data into eight labels (neutral, happy, sad, surprised, fear, disgust, angry, and contempt). Due to using LDA, the performance of categorization via SVM has been obviously enhanced. Grid search is used to find the optimal values for hyperparameters of SVM (C and gamma). The proposed optimized SVM algorithm has achieved an accuracy of 99% and a 98% F1 score.

Drug discovery is still an expensive and time-consuming process where finding the right drug associations is important for therapeutic development. In this paper, a new system is proposed for drug design called PharmaGraphFormer (PGF). It consists of five stages: (i) Data acquisition and preprocessing (DAP), (ii) Feature extraction and feature fusion (FEF), (iii) Molecular representation (MR), (iv) Multi-task prediction, and (v) Explainable artificial intelligence (XAI). This study employs a hybrid graph neural network (GNN)-transformer architecture that combines structural and sequence-based representations. Through DAP, several processes are executed, including the imputation or removal of missing values, outlier rejection, and class balancing. Next, through FEF1, features are extracted to represent the input data efficiently. Initially, compound-protein features are generated to document the interactions and relationships between chemical compounds and their corresponding target proteins. Secondly, drug characterizations are computed to encapsulate the physical, chemical, and structural attributes of each drug. After that, MR is performed using a graph-based molecule representation. Then, a novel model integrating GNNs and graph transformers, termed GNN-T, is proposed. Initially, GNNs represent the most promising deep learning models adept at processing non-Euclidean data. The Graph Transformer layer enhances atom representations by consolidating the representations of adjacent atoms through an attention mechanism. Finally, XAI is applied to explain the internal mechanisms of AI systems, rendering them comprehensible and interpretable. Across five independent runs, the proposed model achieved an accuracy of $0.963\pm 0.002$, a precision of $0.971\pm 0.002$, a recall of $0.958\pm 0.003$, an F1-score of $0.964\pm 0.002$, and a ROC-AUC of $0.993\pm 0.001$. These results demonstrate an outstanding performance when compared with all other models and emphasize that the proposed model is reliable in solving the problems of prioritizing compounds in line with the latest developments in AI-powered virtual screening and drug–target interaction modeling.